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Abstract
Summary In contrast to previously reported elevations in se-
rum sclerostin levels in diabetic patients, the present study
shows that the impaired bone microarchitecture and cellular
turnover associated with type 2 diabetes mellitus (T2DM)-like
conditions in ZDF rats are not correlated with changes in
serum and bone sclerostin expression.
Introduction T2DM is associated with impaired skeletal struc-
ture and a higher prevalence of bone fractures. Sclerostin, a neg-
ative regulator of bone formation, is elevated in serum of diabetic
patients. We aimed to relate changes in bone architecture and
cellular activities to sclerostin production in the Zucker diabetic
fatty (ZDF) rat.
Methods Bone density and architecture were measured by
micro-CT and bone remodelling by histomorphometry in tibiae
and femurs of 14-week-old male ZDF rats and lean Zucker con-
trols (n = 6/group).
Results ZDF rats showed lower trabecular bone mineral density
and bone mass compared to controls, due to decreases in bone
volume and thickness, along with impaired bone connectivity
and cortical bone geometry. Bone remodelling was impaired in
diabetic rats, demonstrated by decreased bone formation rate and
increased percentage of tartrate-resistant acid phosphatase-
positive osteoclastic surfaces. Serum sclerostin levels (ELISA)
were higher in ZDF compared to lean rats at 9 weeks (+40 %,
p < 0.01), but this difference disappeared as their glucose control
deteriorated and byweek 14, ZDF rats had lower sclerostin levels
than control rats (−44 %, p < 0.0001). Bone sclerostin mRNA
(qPCR) and protein (immunohistochemistry) were similar in
ZDF, and lean rats at 14 weeks and genotype did not affect the
number of empty osteocytic lacunae in cortical and trabecular
bone.
Conclusion T2DM results in impaired skeletal architecture
through altered remodelling pathways, but despite altered se-
rum levels, it does not appear that sclerostin contributes to the
deleterious effect of T2DM in rat bone.
Keywords Bone . Sclerostin . Type 2 diabetes . Zucker rats
Introduction
Type 2 diabetes mellitus (T2DM) is a developing pandemic
and an important cause of morbidity and mortality. One major
complication of T2DM is a greater risk of bone fractures,
leading to a decreased quality of life for patients [1].
Moreover, fracture healing is delayed and accompanied by a
higher risk of complications such as infections, non-unions or
mal-unions [2]. Clinical evidence indicates that despite pa-
tients typically possessing normal or higher bone mineral den-
sity (BMD), diabetic bone is more fragile and of poorer qual-
ity [3]. There are multiple pathways by which T2DM affects
bone quality. For example, the accumulation of advanced
glycation end products (AGEs) in bone because of chronic
hyperglycaemia can result in altered collagen cross-linking,
leading to impairment of mechanical properties and reduced
bone strength in diabetic patients [4]. In addition, endocrine
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cross-talk between pancreatic β-cells, fat and bone is also
thought to be important in the pathogenesis of T2DM [5].
Specifically, osteoblasts have been shown to be insulin targets,
with impaired bone formation being a consequence of insulin
deficiency in T2DM [6]. However, other pathogenic mecha-
nisms are also thought to be present which contribute to the
impaired skeletal strength in T2DM.
Cellular and molecular communication between bone cells
is essential to ensure appropriate bone remodelling, which is
crucial for optimal skeletal integrity. One of the most impor-
tant molecular pathways in bone homeostasis is the Wnt sig-
nalling pathway, which is essential for bone formation. A
major regulator of the Wnt pathway is the product of the
SOST gene, sclerostin, which is expressed almost exclusively
in osteocytes and acts as a potent inhibitor of bone formation
[7]. It can bind to bone morphogenetic proteins (BMPs) and
low-density lipoprotein receptor-related proteins 5 and 6
(LRP5/6), inhibiting canonical Wnt/β-catenin signalling,
which is essential for osteoblast activity and bone formation
and is dysregulated in diabetic patients [8, 9]. Recent studies
have shown that circulating sclerostin is elevated in diabetic
patients compared to control subjects [10, 11], while serum
sclerostin and bone expression levels are also increased in
type 1 streptozotocin-induced diabetic rat and type 2 aged
Otsuka Long Evans Tokushima Fatty (OLETF) diabetic rats
[8, 12]. Conversely, the number of sclerostin-positive osteo-
cytes was decreased in bone from diabetic mice, because of a
reduction in osteocyte viability [9]. Recently, it was shown
that treatment with a neutralising antibody targeting sclerostin
reverses the adverse effect of T2DM on bone mass and
strength and improves bone regeneration in rats [13].
However, it is unknown whether an increase in sclerostin pro-
duction by osteocytes is involved in the pathogenesis of the
increased skeletal fragility in diabetic patients.
Previous in vitro work suggests that high glucose concen-
trations alter the mineralisation process in osteoblasts via de-
creased calcium uptake [14]. A study in osteocyte-like cells
showed that a combination of high glucose and the resulting
accumulation of advanced glycation end products (AGEs)
suppress bone formation, likely by increasing sclerostin ex-
pression [15]. However, it remains unclear exactly how a high
glucose environment affects osteocytes and whether altered
sclerostin production is a feature.
The skeletal effects of diabetes in laboratory animals have
been investigated in various rodent models, including genetic
and spontaneously diabetic models that undergo a dynamic
period of disease progression. Of these models, the male
Zucker diabetic fatty (ZDF) fa/fa rat is widely used. These rats
possess a mutation in the gene encoding the leptin receptor,
resulting in obesity and subsequent spontaneous development
of T2DM-like clinical signs, including early hyperlipidaemia
and hyperinsulinaemia, followed by persistent hyperglycaemia
and decreased insulin secretion, as a result of pancreatic β-cell
failure [16]. Research on the effects of leptin in bone has yielded
inconsistent results, illustrated by the absence of leptin signalling
in rodents resulting in an increase [17], a decrease [18] or no
change [19] in bone mass. In terms of skeletal characteristics,
the ZDF rat has beenwell studied. Compared to controls, diabetic
ZDF rats exhibit shorter femoral length, reduced bone formation,
decreases in cortical and trabecular bone mass, and diminished
BMD [13, 20–23].
In this study, we aimed to characterise the effects of diabe-
tes on bone architectural and cellular activities in the ZDF rat
model and to correlate any changes with sclerostin expression
by osteocytes in situ and serum sclerostin concentration. To
explore the mechanisms further, we also aimed to examine the
effect of high glucose concentrations on bone mineralisation
and sclerostin expression by osteoblasts and osteocytes
in vitro.
Materials and methods
Animals and study design
Male ZDF rats (ZDF-Leprfa) and Zucker lean rats (ZDF-Crl)
(n = 6/group) were purchased from Charles River laboratories
(Margate, UK) at 8 weeks of age. Rats were acclimatised to
their housing (21 °C ± 1 °C; 12 h day/night cycle) for 1 week
and fed a high-fat-carbohydrate chow (Purina 5008) (Lab
Diet, USA) ad lib. From week 9, rats were weighed weekly
and blood glucose was measured weekly using a glucometer
(Accuchek Aviva, Roche Diagnostics, Burgess Hill, UK), to
identify the onset of frank diabetes. Blood samples were col-
lected at weeks 9, 11, 13 and 14 for measurement of serum
sclerostin. To measure bone formation rate in trabecular bone,
rats were intraperitoneally injected with calcein (10 mg/kg)
and alizarin red complexone (15 mg/kg) (Sigma-Aldrich), re-
spectively 10 and 3 days prior to euthanasia. At week 14, rats
were sacrificed; right tibiae were dissected for micro-CT anal-
ysis and left tibiae for immunohistochemistry, while right fe-
murs were snap frozen for RNA extraction and left femurs
embedded for bone histomorphometry. All animal procedures
were approved by the Royal Veterinary College’s Ethics and
Welfare committee and were carried out under UK Home
Office licence to comply with the Animals (scientific proce-
dures) Act 1986 (PPL: 70/7859).
Micro-CT analysis of tibiae
Right tibiae were fixed in 10 % neutral-buffered formalin for
24–48 h and stored in 70 % ethanol at 4 °C. The
microarchitecture, BMD for trabecular bone and tissue miner-
al density (TMD) for cortical bone were then evaluated using
high-resolution micro-computed tomography (micro-CT)
(10 μm/pixel, 55 kV, 181 μA skyScan-1172/F Bruker,
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Kontich, Belgium). Whole tibiae were reconstructed using
NRecon version 1.6.9.8 (NRecon®), trabecular and cortical
bone areas were analysed with CT-Analyser (CTAn) version
1.14.4.1 and bone structure was quantified using the built-in
2D and 3D analysis software BATMAN v.1.14.4.1. The
threshold values for the micro-CT analysis of trabecular bone
were chosen to be between 60 and 255 and between 100 and
255 for cortical bone. For analysis of trabecular bone in prox-
imal metaphysis, the 1.5 % of bone length below the appear-
ance of secondary spongiosum was left unanalysed and the
5 % of length following was analysed. The cortical shell was
excluded by operator-drawn regions of interest, and 3D algo-
rithms were used to determine the relevant parameters, which
included bone volume percentage (BV/TV), trabecular thick-
ness (Tb.Th), trabecular number (Tb.N), structure model in-
dex (SMI), trabecular pattern factor (Tb.Pf), trabecular sepa-
ration (Tb.Sp) and degree of anisotropy (DA). Analysis of
cortical bone in midshaft diaphysis was performed using a
0.49-mm-long segment (or 100 tomograms) at 50 % of tibial
length from its proximal end. Cortical bone parameters
consisted of tissue area (Tt.Ar), tissue perimeter (Tt.Pm), bone
area (Ct.Ar), eccentricity (Ecc), cross-sectional thickness
(Ct.Th) and maximum moment of inertia (Imax), a parameter
used to predict an object’s ability to resist torsion.
Bone indentation
Following micro-CT analysis, right tibiae were embedded in
methyl methacrylate (MMA) in order to perform microhard-
ness tests. Microhardness is a measurement of the ability of a
material’s surface to resist indentation with or without perma-
nent indentation on a microstructural scale. Mean bone tissue
microhardness was measured using a Micromet 5104
(Buehler, Lake Bluff, Illinois, USA) equipped with a Vickers
indenter. Ten transverse indentations were performed at
1.1 cm below the growth plate for all embedded bones. A load
of 25 g was applied onto the region of interest for 10 s, which
formed a square-based diamond indentation mark. Vickers
microhardness (Hv), defined as the mean pressure the material
will support under load (expressed in kg/mm2), was calculated
from the equation Hv = 1854.4 × P/d2, where P is the test load
in grammes and d is the mean length of the two diagonals,
expressed in millimetre. The data obtained for each bone sam-
ple were expressed as a mean of 10 indentations.
Bone histomorphometry
Left femurs were fixed in 4 % formaldehyde for 2 days at
4 °C, dehydrated in acetone for 24 h and embedded in
MMA at low temperature to preserve enzymatic activity.
Unstained 8-μm-thick longitudinal sections were used for
fluorescence microscopy to assess mineral apposition rate
(MAR, μm/day). The area of mineralising surfaces was
expressed as a ratio of alizarin red-labelled surfaces to total
bone surfaces (MS/BS, %) and mineral apposition rate (MAR,
μm/day), measured as the average distance between calcein
and alizarin red, divided by the number of days elapsed be-
tween the administration of such labels (7 days). The bone
formation rate was calculated as MS/BS × MAR (BFR/BS,
μm3/μm2/day). Alternatively, sections were stained for tartrate-
resistant acid phosphatase (TRAP) (Leucognost® SP; Merck,
Germany) and counterstained with Mayer’s haematoxylin solu-
tion to visualise osteoclasts in trabecular bone, or stained with
Goldner’s stain to quantify trabecular microarchitecture parame-
ters within the sections. Histomorphometric parameters were
measured in the trabecular bone of themetaphysis, using a region
of interest of 2mmwidth, below the growth plate.Measurements
were performed using image analysis software (Explora Nova,
La Rochelle, France). Histomorphometric parameters were re-
ported in accordance with the American Society for Bone and
Mineral Research Committee nomenclature.
Histology
Left tibiae of ZDF and lean rats were harvested immediately
after sacrifice and fixed in 10 % neutral-buffered formalin for
1 day. All tibiae were subjected to 17 days of decalcification in
14 % ethylenediaminetetraacetic acid (EDTA) at pH 7.4.
Tibiae were then embedded in paraffin and sectioned at 5 μm.
Counting the number of empty lacunae
Five sections representing the whole proximal tibial width
were stained with haematoxylin and eosin (H&E) to quantify
the number of empty osteocytic lacunae in three regions: cor-
tical bone in the diaphysis and trabecular bone in the
metaphysis and epiphysis. Five images for each region of each
bone (n = 6/group) were acquired using light microscopy. All
lacunae in each region were manually counted using dot-
counting morphometry (image J) in order to establish the ratio
of empty lacunae to total lacunae (an indication of osteocytic
death).
Immunohistochemistry for sclerostin
For immunohistochemical labelling, tibial sections were first
incubated with 0.1 % trypsin in PBS for 30 min at 37 °C, then
washed in 0.025 % Triton in PBS (wash buffer). Endogenous
peroxidase activity was blocked using 3 % H2O2 in methanol
(30 min) followed by rinsing with wash buffer. The sections
were blocked with 3 % BSA in 20 % rabbit serum and then
incubated overnight at 4 °C with goat polyclonal anti-mouse
sclerostin antibody (10 μg/ml) (AF1589, R&D Systems) and
polyclonal goat IgG for control sections (AB-108-C, R&D
Systems). Sections were washed and incubated for 30 min in
horseradish peroxidase (HRP)-conjugated secondary antibody
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(rabbit anti-goat, 1:200) (P0160, Dako). They were then
rinsed and HRP-label was visualised by incubating the sec-
tions for 5 min with 3,3′ diaminobenzidine (DAB)-solution.
Three sections for each bone were counterstained briefly with
haematoxylin and imaged using light microscopy to visualise
osteocytes within cortical and trabecular bone. All sclerostin-
positive osteocytes in bones of ZDF and lean rats were man-
ually counted in these regions using image J.
Number and size of adipocytes
One section of each bone (n = 6/group) was stained with H&E
to identify adipocytes and images were acquired using bright
field microscopy and Leica imaging software. The number
and size of adipocytes were measured in the metaphysis. All
adipocytes were manually counted in secondary spongiosum
using dot-counting morphometry (image J). Adipocyte size
was manually drawn and individually measured using image
J.
Cell culture
IDG-SW3 cell line
The mouse osteoblastic-late-osteocytic cell line IDG-SW3
was kindly provided by Prof. Linda Bonewald and cultured
as previously described [24]. Briefly, cells were cultured in
MEM supplemented with 10 % foetal calf serum (FCS),
2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml strep-
tomycin. Fifty units per millilitre of recombinant mouse
interferon-gamma (INF-γ) (Invitrogen) was also added to
the cultures to induce expression of the SV40 large tumour
antigen and maintain cell proliferation. The IDG-SW3 cells
were cultured on rat tail collagen type 1-coated plates (Becton
Dickson Bioscience) at 40,000 cells/cm2 and 33 °C.
Osteogenesis was induced at confluence by replacing medium
with fresh growth medium supplemented with 50 mg/L ascor-
bic acid and 4 mM β-glycerophosphate without IFNγ at
37 °C. Cells were maintained for 30 days in osteogenic medi-
um, which was changed three times weekly.
UMR-106 cell line
The rat osteoblastic-like cell line UMR-106 was cultured in
Dulbecco’s Minimal Essential medium supplemented with
10 % FCS, 2 mM L-glutamine, 100 U/mL penicillin and
100 μg/ml streptomycin at 37 °C for 24 h.
Primary osteoblasts
Primary mouse osteoblastic cells were obtained by sequential
enzyme digestion of excised calvarial bones from 2-day-old
C57BL/6 mice, using a three-step process (1 % trypsin in PBS
for 10 min; 0.2 % collagenase type II in Hanks balanced salt
solution (HBSS) for 30 min; 0.2 % collagenase type II in
HBSS for 60 min). The first two digests were discarded and
the cells resuspended in MEM supplemented with 10 % FCS,
2 mM L-glutamine, 1 % gentamicin, 100 U/ml penicillin,
100 μg/ml streptomycin and 0.25 μg/ml amphotericin. Cells
were cultured for 2–4 days at 37 °C in 5 % CO2 until they
reached confluence. They were then cultured in six-well trays
in MEM supplemented with 2 mM β-glycerophosphate and
50 μg/ml ascorbic acid, with half medium changes every
3 days. Bone nodule formation by osteoblasts was measured
after 28 days of culture.
Incubation of cells with high glucose concentrations
IDG-SW3 and UMR 106 cells were cultured with four differ-
ent concentrations of glucose in six-well plates, using one
plate for each. Glucose was added to the medium so that the
first concentration mimicked normal the glucose concentra-
tion in humans (5.5 mM), the second group represented post-
prandial levels (11 mM), the third group represented uncon-
trolled diabetes (22 mM) and the fourth the very high glucose
typical of ZDF rats (44 mM). Primary osteoblasts were cul-
tured in low and high glucose conditions (5.5 and 22 mM).
IDG-SW3 cells and primary osteoblasts were cultured for
30 days, with supernatants being collected at the end of the
experiment. After termination of the experiment, the cells
were fixed with 4 % paraformaldehyde for 10 min and stained
for mineralisation with alizarin red. Cell layers were imaged at
800 dpi using a high-resolution flat-bed scanner. Binary im-
ages of each individual well were then subjected to automated
analysis (image J), using constant Bthreshold^ and Bminimum
particle^ levels, to determine the surface area of mineralised
bone nodules.
UMR-106 cells were cultured in the four glucose concen-
trations for 48 h and the supernatant collected. Trypsin was
then added to the UMR-106 cells for 5 min at 37 °C to detach
them for RNA extraction.
Quantitative PCR
Right femurs were centrifuged at 10.000 rpm to remove the
bone marrow and then individually powdered with a mortar
and pestle under liquid nitrogen. Total RNA from bones was
extracted using TRIzol® reagent or RNeasy Mini Kit
(Qiagen) according to the manufacturers’ protocols. RNA
concentration and purity were estimated by measurement of
absorbance at 260 and 280 nm, respectively, and RNA integ-
rity by visualisation of ribosomal bands after agarose gel
electrophoresis.
The messenger RNA (mRNA) expression level for SOST
was determined in control and diabetic bones, as well as in
UMR-106 cells. Transcripts were amplified by real-time
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quantitative RT-PCR (qPCR) using SYBRGREENPCRmas-
ter mix (Qiagen) in a 25 μL reaction volume. Amplification
parameters consisted of initial denaturation at 50 °C for
10 min to allow reverse transcription, then 95 °C for initial
denaturation and 35 cycles of one-step PCR (denaturation at
95 °C for 10 s, annealing and extension at 60 °C for 30 s)
using primer pairs with the following sequences: SOST: 5′-
GAGTACCCAGAGCCTCCTCA-3 ′ and 5 ′-AGCA
CACCAACTCGGTGAC-3 ′ , GAPDH : 5 ′ -CTCA
ACTACATGGTCTACATGT- 3 ′ a n d 5 ′ - C TTC
CCATTCTCAGCCTTGACT-3′ (designed using Blast).
Their relative abundance in duplicate cDNA aliquots was
quantified using a standard curve plotted from amplification
of a 10-fold dilution series of DNA generated by conventional
PCR from the same primer pairs and gel purified. Results are
quoted after normalisation to expression of GADPH, which
was unchanged by the treatments. Generation of a single ap-
propriate PCR product was confirmed by melting curve anal-
ysis and periodic agarose gel electrophoresis.
Quantification of sclerostin
Sclerostin levels in rat serum and in the supernatants of UMR-
106, primary osteoblasts and IDG-SW3 cells were quantified
using a Solid Phase Sandwich ELISA (Mouse/Rat SOST kit,
R&D Systems Europe, Ltd., Abingdon, UK) according to the
manufacturer’s recommendations.
Statistics
Data are presented as mean ± SD. Statistical analyses
were conducted using GraphPad Prism® (v. 6.01 for
Windows; GraphPad Software Inc., USA). Comparisons
between diabetic and lean rats were performed using
unpaired t tests. Multiple comparisons for in vitro stud-
ies were performed using one-way analysis of variance,
with Dunnett’s post hoc test where appropriate. Other
multiple comparisons were performed using a two-way
analysis of variance using the Sidak post hoc test where
appropriate. P < 0.05 was considered to be statistically
significant. The in vitro results shown are representative
of three independent experiments.
Results
Body weight and blood glucose levels in Zucker diabetic
rats
Development of diabetes in ZDF rats was monitored by week-
ly measurements of body weight and blood glucose levels.
Body weights of ZDF rats were higher compared to lean rats
at all time points (p < 0.0001). However, this difference tended
to disappear as the rats became more diabetic, with values
reaching 237 g for lean rats and 312 g for ZDF rats at 9 weeks
and 327 g for lean rats and 362 g for ZDF rats at 14 weeks.
Furthermore, ZDF rats exhibited dramatically elevated levels
of blood glucose compared to controls, with values of 24.8
and 7.8 mmol/L, respectively, at 9 weeks (2.2-fold higher
(p < 0.0001)) and 30.6 and 7.1 mmol/L, respectively, at
14 weeks (3.3-fold higher (p < 0.0001)). These data confirm
the expected impairment of glycaemic control in ZDF rats.
Effect of diabetes on bone mineral density, trabecular
and cortical bone mass and architecture in ZDF rats
We examined bone mass and architecture in ZDF rats and lean
control rats. ZDF rats exhibited a lower tibial bone length
(4.7 %, p < 0.001) compared with lean rats (Table 1).
Trabecular BMD was also lower in the ZDF rats (by 22.2 %,
p < 0.01) compared with lean rats, while cortical TMD was
not different (Table 1). ZDF rats exhibited lower trabecular
bone mass, demonstrated by decreased BV/TV and Tb.Th
(18.7 %, p < 0.001 and 11.7 %, p < 0.0001, respectively),
compared to the lean controls. They also exhibited impaired
connectivity, manifested by a substantial increase in Tb.Pf
(91.1 %, p < 0.05). There was no significant effect of diabetes
on Tb .Sp , Tb .N , SMI o r DA (Tab l e 1 ) . Bone
histomorphometry measurements in trabecular bone using
Goldner staining suggested similarly lower trabecular bone
mass in diabetic rats, indicated by lower in BV/TV, Tb.Th
and Tb.N (43.4 % (p < 0.001), 26.2 % (p < 0.01) and
23.8 % (p < 0.05), respectively) in ZDF rats compared to lean
controls. The separation between trabeculae was increased by
59 % (p < 0.05) in ZDF rats, although this was not observed
using micro-CT measurements (Table 1).
Consistent with trabecular bone changes, cortical bone ge-
ometry was also abnormal in ZDF rats. Analysis half-way
along the bone length showed reductions in cortical area and
perimeter, illustrated by lower Tt.Ar, Tt.Pm, Ct.Ar (12.7 %
(p < 0.01), 7.6 % (p < 0.01) and 15.5 % (p < 0.01), respec-
tively) in ZDF rats compared to lean rats. Imax and Ecc were,
respectively, 28.6 % (p < 0.01) and 4.3 % (p < 0.05) lower in
ZDF rats, suggesting that diabetic bone may have reduced
strength. Furthermore, transverse bone sections revealed a de-
crease in Ct.Th of the cortical wall by 7.9 % (p < 0.01) in ZDF
rats (Table 1).
Effect of diabetes on cortical bone microhardness in ZDF
rats
To examine the relationship between bone structure and its
mechanical resistance to forces, microhardness tests were per-
formed on cortical bone. No significant difference was ob-
served between the microhardness of cortical bone in ZDF
rats (53.94 ± 3.02 kg/mm2) compared to controls
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(54.30 ± 2.58 kg/mm2) (p = 0.8318), suggesting that the struc-
tural integrity of ZDF cortical bone is maintained (data not
shown).
Effect of diabetes on bone turnover
We next examined whether bone remodelling is affected by
diabetes. Bone histomorphometry showed uncoupling of bone
remodelling in ZDF rats, as there was a substantially increased
percentage of TRAP-positive osteoclastic surfaces (108.9 %
higher; p < 0.05) compared to lean rats (Fig. 1a). Analysis of
bone formation activities showed that MAR and BFR were
lower in ZDF rats compared to lean rats (by 61.8 %,
p < 0.0001 and 69.6 %, p < 0.001, respectively; Fig. 1b, c).
Effect of diabetes on serum sclerostin levels
Serum sclerostin levels in ZDF and lean rats were assessed by
ELISA. At 9 weeks of age, sclerostin levels were 39.8 %
higher (p < 0.01) in ZDF compared to lean rats. However, this
difference disappeared at 11 and 13 weeks, as glycaemic con-
trol deteriorates, with sclerostin levels ultimately being 43.5%
lower (p < 0.0001) in ZDF than lean rats at 14 weeks of age
(Fig. 2a).
Effect of diabetes on numbers of sclerostin-secreting
osteocytes and SOST mRNA levels
We quantified the number of sclerostin-positive osteocytes in
epiphyseal, cortical and trabecular bone using immunohisto-
chemistry and qPCR (Fig. 2c). No significant differences were
identified in the number of sclerostin-positive osteocytes in
any of these regions between 14-week-old ZDF and lean rats
(Fig. 2d). Similarly, no difference was observed in sclerostin
mRNA levels in bone between ZDF and lean rats at this age,
indicating that sclerostin levels in serum do not reflect current
expression levels in bone (Fig. 2b).
Effect of diabetes on the number of empty osteocytic
lacunae and adipocytes in ZDF rats
To establish whether diabetes could reduce osteocyte viability,
we quantified the number of empty osteocytic lacunae in
epiphyseal, cortical and trabecular bone (Fig. 3a). The number
of dead osteocytes was similar between ZDF and lean rats in
cortical, trabecular and epiphyseal regions (Fig. 3b).
The effect of diabetes on the number and size of adipocytes
was also investigated (Fig. 3c). There was no difference in
adipocyte number between diabetic and lean rats (Fig. 3d),
but adipocyte size was increased by 68 % (p < 0.0001) in
ZDF rats compared to lean rats (Fig. 3e).
Effect of high glucose concentrations on sclerostin
production and mineralisation by osteoblastic
and osteocytic cells
To establish whether hyperglycaemia is a key factor mediating
the observed effects of diabetes on bone in ZDF rats, we
examined the effect of high glucose concentrations on
sclerostin production by the UMR osteoblastic cell line and
primary osteoblasts. Sclerostin production by UMR-106 cells
was increased by 59 % (p < 0.0001) and 79.1 % (p < 0.0001)
in the presence of 22 and 44 mM glucose, respectively
(Fig. 4a). Similarly, sclerostin mRNA expression increased
in parallel with glucose concentrations (11 mM (+59.3 %),
22 mM (+181 %) and 44 mM (+246.2 %)) (Fig. 4b). In con-
trast, sclerostin production by primary osteoblasts was not
affected by high glucose concentrations (Fig. 4d). We could
Table 1 Micro-CT and histomorphometric measurements of trabecular
and cortical bone architecture in 14-week-old ZDF and Zucker lean rats
Parameters Zucker lean rats ZDF rats
Length of tibia (mm) 38.7 ± 0.7 36.9 ± 0.5***
Trabecular architecture
BV/TV (%) 16.95 ± 1.17 13.78 ± 1.08***
Tb.Th (mm) 0.0992 ± 0.0019 0.0875 ± 0.0027****
Tb.N (number/mm) 1.708 ± 0.103 1.574 ± 0.125
Tb.Pf (factor/mm) −2.888 ± 2.207 −0.257 ± 1.132*
Tb.Sp (mm) 0.932 ± 0.037 0.899 ± 0.038
SMI 1.037 ± 0.166 1.194 ± 0.077
DA 2.166 ± 0.126 2.151 ± 0.082
BMD (g/cm3) −0.0011 ± 0.0115 −0.0262 ± 0.0134
Cortical architecture at 50 %
Tt.Ar (mm2) 5.90 ± 0.30 5.14 ± 0.43**
Tt.Pm (mm) 9.77 ± 0.30 9.03 ± 0.39**
Ct.Ar (mm2) 4.51 ± 0.20 3.81 ± 0.31**
Ecc 0.731 ± 0.015 0.699 ± 0.020*
I max (mm4) 3.96 ± 0.42 2.83 ± 0.44**
Ct.Th (mm) 0.587 ± 0.017 0.541 ± 0.024**
TMD (g/cm3) 1.270 ± 0.015 1.277 ± 0.013
Trabecular architecture
with histomorphometry
BV/TV (%) 25.43 ± 3.04 14.40 ± 4.04***
Tb.Th (mm) 0.0640 ± 0.0078 0.0472 ± 0.0063**
Tb.N (number/mm) 3.978 ± 0.260 3.033 ± 0.712*
Tb.Sp (mm) 0.188 ± 0.017 0.299 ± 0.090*
Measurements were either made in the proximal tibial metaphysis of ZDF
rats and Zucker lean rats using micro-CT or in sections of the proximal
femoral metaphysis sections using histomorphometry. Measurements of
cortical architecture were made using micro-CT in the tibial midshaft
diaphysis of ZDF and Zucker lean rats. Mean ± SD of n=6 rats/group
BV/TV bone volume percent, Tb.N trabecular number, Tb.Pf trabecular
pattern factor, Tb.Th trabecular thickness, Tb.Sp trabecular separation,
SMI structure model index, DA degree of anisotropy, Tt.Ar tissue area,
Tt.Pm tissue perimeter, Ct.Ar bone area, Ecc eccentricity, I max maximal
moment of inertia, Ct.Th cross-sectional thickness
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 versus lean controls
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not detect sclerostin mRNA and protein expression in IDG-
SW3 cells after analysis at various cell passage numbers.
However, in this cell line, high glucose concentrations im-
paired mineralisation, as glucose concentrations of 11, 22
and 44 mM decreased mineralisation by 14.9 % (p < 0.01),
26 % (p < 0.0001) and 24.5 % (p < 0.0001), respectively
(Fig. 4c). Similarly, bone nodule formation by primary osteo-
blasts was reduced by 81 % (p < 0.0001) in the presence of a
high glucose concentration (Fig. 4e).
Discussion
This study is novel in two regards. Firstly, in the use of a rat
model of T2DM to investigate the effects of diabetes on bone
structural properties and turnover in parallel with bone
sclerostin expression levels and osteocyte viability and sec-
ondly, in modelling the effect of hyperglycaemia on matrix
mineralisation and sclerostin production in osteoblasts and
osteocytes in vitro. We demonstrate that ZDF rats have
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Fig. 2 Serum and bone sclerostin levels in ZDF and control Zucker rats.
a Serum sclerostin levels at 9 and 14 weeks of age, measured by ELISA.
b Bone sclerostin mRNA expression normalised to GAPDH, quantified
by qPCR. cRepresentative longitudinal section of the cortical metaphysis
region of the tibiae in which quantification was performed. d Ratio of
number of sclerostin-positive osteocytes to total number of osteocytes,
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Fig. 1 Bone turnover parameters measured by bone histomorphometry
in ZDF and non-diabetic Zucker rats. Measurements were performed by
bone histomorphometry on trabecular femoral sections of 14-week-old
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Fig. 4 Effects of high glucose concentrations on sclerostin production by
UMR 106 cells and primary osteoblasts and in vitro mineralisation of
IDG-SW3 cells and primary osteoblasts. UMR-106 cells and IDG-SW3
were cultured in various glucose concentrations (5.5, 11, 22 and 44 mM)
while primary osteoblasts were cultured in only two concentrations (5.5,
22 mM). a Sclerostin levels measured in the supernatant of UMR-106
cells by ELISA. b Sclerostin mRNA expression in UMR-106 cells,
measured using qPCR. c Quantification of mineralisation by IDG-SW3
cells after 30 days of culture. d Sclerostin levels measured in the super-
natant of primary osteoblasts by ELISA. e Quantification of
mineralisation by primary osteoblasts after 4 weeks of culture. Bars rep-
resent mean ± SD of n = 6 wells/group. **P < 0.01, ****P < 0.0001
versus control. Experiments were carried out in triplicate, except for pri-
mary osteoblasts, in which one experiment was performed
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Fig. 3 Bone histology in ZDF and non-diabetic Zucker rats. a
Representative haematoxylin-eosin staining of tibiae showing the empty
osteocytic lacunae and osteocytes within the trabecular bone. b Ratio
between number of empty osteocytic lacunae/ total number of lacunae.
c Representative haematoxylin-eosin staining of tibiae along with the
distribution of adipocytes in lean (left) and ZDF rats (right). d Number
of adipocytes. e Surface of adipocytes. Bars represent mean ± SD of n = 6
rats/group. ****P < 0.0001 versus control
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abnormal bone architecture, associated with lower bone re-
modelling. Although high glucose concentrations led to an
increase in sclerostin production by UMR-106 osteoblastic
cells, this effect was not replicated in primary osteoblasts.
Furthermore, bone sclerostin levels and the number of viable
osteocytes were unchanged in diabetic bone, implying that
altered sclerostin levels might not be indicative of impaired
bone structure in diabetic rats.
We used a well-established rodent model of T2DM that
progressively develops the typical pathology of and shares a
number of common metabolic disturbances with human pa-
tients, including the insulin resistance, hyperglycaemia and
hyperinsulinaemia [21]. ZDF rats showed highly abnormal
glucose control at 14 weeks of age. Diabetes also impaired
bone mass, evidenced by a decrease in trabecular bone vol-
ume, because of reductions in trabecular thickness and im-
paired connectivity. Cortical bone was similarly affected, as
it exhibited significantly reduced cortical bone area and thick-
ness and the suggested resistance to torsion implies reduced
bone strength if the materials properties are similar. These
results are in agreement with other investigations that demon-
strated impaired bone mass and strength in ZDF rats after
onset of overt diabetic symptoms [13, 20–23], and they col-
lectively confirm that T2DM adversely affects trabecular
microarchitecture and cortical bone geometry. However, the
micro-CT analysis showed significantly lower trabecular, but
not cortical, BMD in ZDF rats, which contrasts with the phe-
notype of diabetic patients, who usually have normal or higher
BMD [3]. Considering the impaired bone structural properties
and Imax, we would also expect lower mechanical resistance
and strength, but our results demonstrate that microhardness
of cortical bone was unchanged in diabetic rats. However,
microhardness relates mostly to the degree of cortical bone
mineralisation rather than the arrangement of collagen fibres
[25]. In diabetic rats, it is likely that changes in mechanical
properties are mainly caused by collagen cross-linking, fol-
lowing the production of AGEs with hyperglycaemia [26].
Hence, as microhardness mainly relates to the mineral com-
ponent of bone, and cortical mineral density was not affected,
these data may not accurately reflect the changes in bone
strength in diabetic bone that have been previously shown in
the literature using a technique such as three-point bending,
which specifically measures bone strength [21].
The deleterious effects of diabetes on bone mass and archi-
tecture were confirmed in histological sections using bone
histomorphometry. Consistent with the decreases in trabecular
and cortical bone mass, histomorphometric evaluation of trabec-
ular bone cellular activities showed significantly uncoupled bone
remodelling in diabetic bone, illustrated by increased osteoclast
surfaces combined with decreased mineral apposition rate and
bone formation rate. The observed reduction in bone formation
in ZDF rats is consistent with the results of previously published
studies [13, 27]. Although, previous studies of the effect of
diabetes on bone resorption have shown no difference in bone
resorption between ZDF diabetic and control rats [28] or in-
creased bone resorption in ZDF rats [18], the results of most
studies performed in other diabetic rodent models are consistent
with ours [29, 30].
Various mechanisms may explain the architectural changes
observed in diabetic bone. In addition to decreased leptin
levels [22], hyperglycaemia is a possible cause of skeletal
deterioration in diabetic ZDF rats [21, 23]. It has been shown
that hyperglycaemia can trigger oxidative stress, resulting in al-
teration of bone architecture [31].Moreover, hyperglycaemia and
the resulting excessive formation of AGEs have been suggested
to exert a deleterious skeletal effect by increasing stiffness of the
collagen network and suppressing in vitro bone formation [32].
Although we were not able to assess the formation of AGEs in
bone in this study, it is likely that ZDF rats had increased skeletal
levels of AGEs [33], which would impair osteoblastic cell func-
tion through modification of type I collagen. This would be
consistent with the observed increase in osteoclast surfaces, since
AGEswere shown to enhance osteoclastmaturation and function
[34]. Therefore, the microarchitectural deterioration of bone in
the diabetic ratsmay partly be a consequence of the accumulation
of AGEs. Recent evidence suggests that a combination of
hyperglycaemia and AGEs suppresses bone formation and in-
hibits bonematrix mineralisation by increasing sclerostin expres-
sion in osteocyte-like MLO-Y4-A2 cells [15]. It has been sug-
gested that high glucose concentrations stimulate sclerostin se-
cretion in osteoblastic and osteocytic cell lines. Consistent with
previous data, our results show increased sclerostin production in
UMR-106 cells with increasing glucose concentrations, implying
a stimulatory effect of hyperglycaemia on sclerostin production
[35, 36]. However, we could not detect sclerostin expression in
the osteocytic cell line IDG-SW3 at any stage of differentiation,
suggesting that IDG-SW3 cells might not be suitable for the
study of sclerostin expression. Exposure of osteocytic IDG-
SW3 cells to high glucose levels inhibited in vitro mineralisation
in a concentration-dependent manner. These findings are in
agreement with previous in vitro studies showing that high glu-
cose concentrations impair calcium deposition and decrease
mineralisation in osteoblast cultures [14, 37], independently of
an increase in sclerostin.
In addition to the observed deleterious effect of T2DM on
bone mass and architecture, this study clearly demonstrates
that diabetes decreases bone formation. Several studies have
identified impaired bone formation as a consequence of sup-
pressed osteoblastogenesis, based on reduced expression of
bone formation markers such as osteocalcin and Runx2 [8,
13, 20]. As the Wnt signalling pathway is crucial for bone
formation and regulates the expression of Runx2, it has been
suggested that diabetes decreases osteoblastogenesis through
the inhibition of Wnt signalling [8]. Based on the inhibitory
action of sclerostin on Wnt signalling, we anticipated that
sclerostin expression levels would be elevated in diabetic rats,
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potentially causing the impaired osteoblastogenesis. In accor-
dance with clinical studies on T2DM patients [10, 11], 9-
week-old ZDF rats had increased circulating levels of
sclerostin. However, this difference disappeared as the rats
got older and glucose control deteriorated still further, ulti-
mately resulting in lower serum sclerostin levels in the diabet-
ic rats at 14 weeks of age. Thus, it could be that sclerostin
levels in serum correlate better with the degree of glucose
control remaining or the age of the rats, rather than the pres-
ence or absence of diabetes. Sclerostin levels greatly increase
with age in mice and humans [38, 39], thus it seems unlikely
that age contributes to the decrease in sclerostin levels ob-
served in our study at 14 weeks of age. However, we cannot
exclude that the lower bone mass observed in ZDF rats at
14 weeks may imply the presence of fewer osteocytes and
consequently reduced sclerostin release into the serum of dia-
betic rats.
Several studies in humans and mice have revealed that
serum sclerostin levels do not necessarily reflect contempora-
neous differences in the local production of sclerostin in bone
[40, 41]. Due to this inconsistency between serum sclerostin
and bone mRNA expression, we investigated sclerostin ex-
pression levels in bone at both the mRNA and protein levels.
We found no differences in bone sclerostin mRNA expression
and the number of sclerostin-positive osteocytes between ZDF
and control rats. One possible limitation could be the tech-
nique used to assess protein levels, as immunohistochemistry
allows the enumeration of sclerostin-secreting osteocytes, but
does not quantify the level of sclerostin produced per osteo-
cyte. In contrast, results from a previous study [8] showed that
in streptozotocin-induced diabetic rats, a model for T1DM,
there was increased expression of sclerostin mRNA in bone.
This discrepancy could be due to the diabetic model used and
suggests that sclerostin levels in bone may be increased in
T1DM rats but not in T2DM. However, in another murine
model of T1DM, there was a down-regulation of sclerostin
mRNA levels in bone, which was ascribed to increased oste-
ocyte apoptosis [9]. In addition, in our study, there was no
difference in the number of empty osteocyte lacunae between
ZDF and control groups, implying no change in osteocyte
viability. Thus, our data collectively indicate that the alter-
ations in microarchitecture and bone turnover associated with
T2DM-like conditions in ZDF rats are not a consequence of
elevated sclerostin expression and that in this model sclerostin
levels in serum do not correlate with its expression in bone.
Significantly, Roforth et al. [41] suggested that circulating
sclerostin is derived from several other non-skeletal sources, as
well as from articular cartilage chondrocytes [39], and all this
information combined implies that measurement of serum
sclerostin may not be useful as a predictive biomarker for im-
paired bone formation. Serum sclerostin levels have been mea-
sured in many clinical conditions and consistent changes were
not always observed [42], suggesting the need for a better
understanding of the factors that control sclerostin production
by osteocytes and possibly more consistent serum sclerostin as-
says. Our in vitro data also suggest that sclerostin levels in bone
cell supernatants do not always correlate with bone formation
and glucose levels, as an increase in sclerostin production was
observed in UMR 106 osteoblastic cells when cultured with high
glucose concentration, while this was not confirmed in primary
osteoblasts, which express low levels of sclerostin. Similarly,
although the osteocytic cell line IDG-SW3 was previously
shown to produce sclerostin mRNA and protein with differenti-
ation [24], we and others have found no sclerostin expression in
this cell line, despite analysis at various cell passage numbers.
The cause of this discrepancy is unclear but could be due to
immunoassay variability.
As the altered bone turnover observed in the diabetic rats
could neither be explained by a sclerostin-mediated inhibition
of Wnt signalling pathway, nor by a reduction in osteocyte via-
bility, we examined whether impaired osteoblastic differentiation
could be at fault, whichwould be indicated by increased numbers
of adipocytes. Bone marrow mesenchymal stem cells
(BMMSCs) have the ability to differentiate into various cell
types, including osteoblasts and adipocytes. Obesity and diabetes
are associatedwith bonemarrow adiposity and increased produc-
tion of tumour necrosis factor-α (TNF-α), an inflammatory cy-
tokine that suppresses osteoblastogenesis and mineralisation
[43]. We hypothesised that BMMSCs may have differentiated
into adipocytes rather than osteoblasts and, their differentiation
being crucial for bone remodelling [44], this could contribute to
the decreased BFR observed in the diabetic rats. Obesity and
T2DM are characterised by an elevated fat mass, mainly
resulting from hypertrophy, rather than hyperplasia of adipocytes
[45]. Consistent with this, ZDF rat adipocytes were larger than
controls, but there was no difference in the number of adipocytes
within the bone marrow. Nevertheless, the enlarged adipocytes
observed in diabetic conditions might be another mediator of the
observed skeletal fragility.
In conclusion, this is the first extensive study to examine the
role of sclerostin in the pathogenesis of T2DM using ZDF rats.
Taken together, our results demonstrate that T2DM has a delete-
rious effect on trabecular bone architecture and cortical bone
geometry due to lower bone formation and higher bone resorp-
tion. However, our data indicate that the alterations in
microarchitecture and bone turnover associated with T2DM-
like conditions in ZDF rats are not a consequence of elevated
sclerostin expression. As T2DM likely affects bones via multiple
mechanisms, further studies are warranted to elucidate the vari-
ous factors that account for the increased bone fragility observed
in T2DM patients.
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